LEADER 01490nam  2200433Ia 450 
001 9910698890203321
005 20090505172353.0
035   $a(CKB)5470000002396960
035   $a(OCoLC)320274696
035   $a(EXLCZ)995470000002396960
100   $a20090505d2009      ua             0
101 0 $aeng
135   $aurcn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrugs on specialty tiers in part D$b[electronic resource] /$fElizabeth Hargrave, Jack Hoadley, Katie Merrell
210  1$aWashington, DC :$cMedPAC,$d[2009]
215   $a21 pages $cdigital, PDF file
225 1 $a[MedPAC contract research series] ;$vno. 09-1
300   $aTitle from title screen (viewed on May 5, 2009).
300   $a"A study conducted by staff from NORC at the University of Chicago and from Georgetown University."
300   $a"February 2009."
606   $aPharmaceutical services insurance$zUnited States
606   $aMedicare
615  0$aPharmaceutical services insurance
615  0$aMedicare.
700   $aHargrave$b Elizabeth$01390567
701   $aHoadley$b Jack$01388689
701   $aMerrell$b Katie$01422653
712 02$aMedicare Payment Advisory Commission (U.S.)
712 02$aNORC (Organization)
712 02$aGeorgetown University.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698890203321
996   $aDrugs on specialty tiers in part D$93547612
997   $aUNINA